Anti-LY6G6E/ C6orf22/ G6e monoclonal antibody

Anti-LY6G6E/ C6orf22/ G6e antibody for FACS & in-vivo assay

Target products collectionGo to LY6G6E/LY6G6E products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)

pdfMSDSpdfCOApdfDatasheet

Product information

Catalog No.Product NameSpecies Reactivity
GM-Tg-hg-MP2607-Ab-1/ GM-Tg-hg-MP2607-Ab-2Anti-Human LY6G6E monoclonal antibodyHuman
GM-Tg-rg-MP2607-Ab-1/ GM-Tg-rg-MP2607-Ab-2Anti-Rat LY6G6E monoclonal antibodyRat
GM-Tg-mg-MP2607-Ab-1/ GM-Tg-mg-MP2607-Ab-2Anti-Mouse LY6G6E monoclonal antibodyMouse
GM-Tg-cynog-MP2607-Ab-1/ GM-Tg-cynog-MP2607-Ab-2Anti-Cynomolgus/ Rhesus macaque LY6G6E monoclonal antibodyCynomolgus/ Rhesus macaque
GM-Tg-felg-MP2607-Ab-1/ GM-Tg-felg-MP2607-Ab-2Anti-Feline LY6G6E monoclonal antibodyFeline
GM-Tg-cang-MP2607-Ab-1/ GM-Tg-cang-MP2607-Ab-2Anti-Canine LY6G6E monoclonal antibodyCanine
GM-Tg-bovg-MP2607-Ab-1/ GM-Tg-bovg-MP2607-Ab-2Anti-Bovine LY6G6E monoclonal antibodyBovine
GM-Tg-equg-MP2607-Ab-1/ GM-Tg-equg-MP2607-Ab-2Anti-Equine LY6G6E monoclonal antibodyEquine

Size： 1mg | 10mg | 100mg



Product Description

Catalog No.GM-Tg-hg-MP2607-Ab-1/ GM-Tg-hg-MP2607-Ab-2; GM-Tg-rg-MP2607-Ab-1/ GM-Tg-rg-MP2607-Ab-2;
GM-Tg-mg-MP2607-Ab-1/ GM-Tg-mg-MP2607-Ab-2; GM-Tg-cynog-MP2607-Ab-1/ GM-Tg-cynog-MP2607-Ab-2;
GM-Tg-felg-MP2607-Ab-1/ GM-Tg-felg-MP2607-Ab-2; GM-Tg-cang-MP2607-Ab-1/ GM-Tg-cang-MP2607-Ab-2;
GM-Tg-bovg-MP2607-Ab-1/ GM-Tg-bovg-MP2607-Ab-2; GM-Tg-equg-MP2607-Ab-1/ GM-Tg-equg-MP2607-Ab-2
Products NameAnti-LY6G6E monoclonal antibody
Formatmab
Target NameLY6G6E
Protein Sub-locationTransmembrane Protein
Category of antibodyFACS/Biofunctional Antibody
Derivation (species)Mouse
CH1+2+3 Isotype
(Receptor identification)		IgG
Type of Light Chain (VD-LC)N/A
Expression platformMammalian Expression
Bioactivity validationBinding affinity is validated by using flow cytometry with antigen overexpressed cell line. The biofunction of antibodies are validated in cell-based assay (IC50 or EC50 TBD).
TagFc
Products descriptionPre-made anti-LY6G6E benchmark inhibitory monoclonal antibody(mab) (blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, FACS,ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic)
Purity Purity: ≥95% (SDS-PAGE)
Application Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Formulation & Reconstitution Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4);
For PSB2, reconstituted with 0.9% sodium chloride;
For PBS, reconstituted with ddH2O.
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference




    Data / case study


    Click to get more Data / Case study about the product.



    Associated products


    CategoryCat No.Products Name
    Target AntigenProducts DevelopingMulti-species LY6G6E/ C6orf22/ G6e VLP (virus-like particle) (Products Developing)


    Target information

    Target IDGM-MP2607
    Target NameLY6G6E
    Gene ID79136
    Gene Symbol and SynonymsC6orf22,G6e,LY6G6E
    Uniprot AccessionN/A
    Uniprot Entry Name
    Protein Sub-locationTransmembrane Protein
    Category
    DiseaseN/A
    Gene EnsemblENSG00000224708
    Target ClassificationN/A

    The target: LY6G6E, gene name: LY6G6E, also named as C6orf22, G6e. LY6G6E belongs to a cluster of leukocyte antigen-6 (LY6) genes located in the major histocompatibility complex (MHC) class III region on chromosome 6. Members of the LY6 superfamily typically contain 70 to 80 amino acids, including 8 to 10 cysteines. Most LY6 proteins are attached to the cell surface by a glycosylphosphatidylinositol (GPI) anchor that is directly involved in signal transduction (Mallya et al., 2002 [PubMed 12079290]).[supplied by OMIM, Mar 2008].



    About Gmab

    GDU
    GDU



    GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.

    Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.